Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
Pfizer(PFE) stock is priced at $27.43, giving the company a market capitalization of 156.2B. It carries a P/E multiple of 19.63 and pays a dividend yield of 6.5%.
As of 2026-03-18, Pfizer(PFE) stock has fluctuated between $26.56 and $27.76. The current price stands at $27.43, placing the stock +3.3% above today's low and -1.2% off the high.
Pfizer(PFE) shares are trading with a volume of 60.1M, against a daily average of 41.06M.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.
PFE News
Pfizer Inc. (NYSE:PFE) on Tuesday announced topline results from the Phase 2 FOURLIGHT-1 study in pretreated metastatic breast cancer patients. The trial, whic...
Anytime is a great time to invest in stocks. The catch is that you must choose the right stocks. The current market dynamics, including high volatility and wor...
Pfizer (PFE) announced on Tuesday that its investigational breast cancer therapy, atirmociclib, as part of a combination regimen, reached the main goal in a lat...
Analyst ratings
55%
of 29 ratingsMore PFE News
Pfizer (PFE) announced topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant...
HSBC raised the firm’s price target on Pfizer (PFE) to $32 from $29 and keeps a Buy rating on the shares. The firm says the uncertain macro backdrop, rising geo...
Advertisement How Pfizer (PFE) looks after recent performance Pfizer (PFE) shares closed at $26.61, with a 3.5% decline over the past month and a 4.2% return...
Key Points Pfizer’s revenue reached $100 billion a few years ago, driven by its dominance in coronavirus treatments and prevention. In recent times, it’s face...
Pfizer has started new clinical studies tied to its tafamidis and etrasimod franchises, including a Phase 1 tafamidis bioequivalence trial. The company is adva...
China has approved Pfizer's GLP-1 obesity therapy Xianweiying (ecnoglutide), granting the company commercialization rights in mainland China. The therapy was o...
Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Claim 70% Off TipRanks Premium Unlock hedge fund-lev...